TandemAI raises $25 Million Seed & Pre-series financing to expand its wet lab operations

TandemAI has announced it has raised $25 million in Seed and pre-Series A financing to advance its proprietary computational platform and expansion of its wet lab operations.

The company will tightly integrate the computational platform with wet labs for biophysics, medicinal chemistry, and biology in order to accelerate the design and optimization of drug candidates for partners. The round was led by OrbiMed and Chengwei Capital.

David Wang, Senior Managing Director and Partner, OrbiMed: “Advances in artificial intelligence tools rooted in rigorous biophysics represent a new frontier in drug discovery. TandemAI has assembled an outstanding core team to leverage this opportunity with a vision for creating a new drug discovery engine that is based on accurate quantum mechanics, large scale experimental data, and artificial intelligence.”

Jeff He, MBA, co-founder, and CEO, TandemAI: “The investments by OrbiMed and Chengwei Capital, both leading venture firms, are strong votes of confidence in our strategy, business model, and team. The funds will accelerate our expansion and enable us to attract the best talent for our platform and discovery operations.”

TandemAI’s co-founders bring deep experience and exceptional track records in building, leading, and financing innovative drug discovery and development organizations. Mr. He has more than 20 years of experience in senior business leadership roles at companies, including most recently at HiFiBiO, where he served as co-founder and COO, and Harbour BioMed, where he was a co-founder and CFO. Wei Tang, Ph.D., TandemAI’s COO, was previously the CEO of Shanghai ChemPartner and a member of its board of directors. Before joining ChemPartner, he served at Merck in several senior research roles, with his latest position as a Distinguished Senior Investigator.

TandemAI is rapidly setting up state-of-the-art wet labs and high-performance computing clusters in China.

www.tandemai.com